PTGS2 and esophageal adenocarcinoma: Esophageal cancer prevention strategies [58], the role of inflammatory mediators in the disease pathophysiology [24], as well as encouraging experimental and epidemiological data on chemoprophylaxis with NSAIDs in patients with Barrett’s esophagus have been recently reviewed [59], along with a body of evidence supporting a role for COX-2 in the pathogenetic sequence leading to esophageal adenocarcinoma [60,61].